Roche receives blood cancer drug blow after Gazyva trial fails to meet endpoint
Swiss drugmaker Roche said trials showed its new blood cancer drug Gazyva failed to deliver significant improvements over an older medicine in people with an aggressive type of blood cancer, a blow in its fight against competition from biosimilars. Gazyva did not significantly reduce the risk of disease worsening or death for people with previously untreated diffuse large B-cell lymphoma, over current drug Rituxan in a phase III GOYA study, Roche said on Monday. Diffuse large B-cell lymphoma is the most common form of non-Hodgkin's lymphoma.